Abstract
MicroRNAs (miRNAs) are non-coding RNAs of ~22 nucleotides which act as down regulators of gene expression in the post-transcription level and/or in the translation level. Several studies have shown that the process of their maturation is rather crucial for the development of cardiovascular system thus their regulation (up-,down-) is implicated with many cardiac pathologies. This is evaluated through their circulating levels which are reliable, stable and the changes in their serum profiles are representative of tissue alterations serum levels. Furthermore, they have been shown to participate in cardiovascular disease pathogenesis including atherosclerosis, coronary artery disease, myocardial infarction, heart failure cardiac arrhythmias and aortic stenosis. In the present review, we will first describe i) the process of miRNAs’ maturation ii) their role in the cardiovascular development, iii) their role as biomarkers of cardiac diseases, iv) the cardiac myo-miR families and the v) their role in cardiac remodeling and the development of cardiac diseases. Second we will review the miRNA families that participate in aortic stenosis separated according to its main pathways (imflammation, fibrosis, calcification). Finally, we will describe the miRNAs that participate in the development of aortic aneurysm and aortic dissection according to their serum levels.
Keywords: microRNAs, aortic disease, aortic stenosis, aortic dissection, aortic aneurysm.
Current Topics in Medicinal Chemistry
Title:MicroRNAs in Aortic Disease
Volume: 13 Issue: 13
Author(s): Manolis Vavuranakis, Maria Kariori, Dimitrios Vrachatis, Konstantinos Aznaouridis, Gerasimos Siasos, Eleni Kokkou, Savvas Mazaris, Carmen Moldovan, Konstantinos Kalogeras, Dimitris Tousoulis and Christodoulos Stefanadis
Affiliation:
Keywords: microRNAs, aortic disease, aortic stenosis, aortic dissection, aortic aneurysm.
Abstract: MicroRNAs (miRNAs) are non-coding RNAs of ~22 nucleotides which act as down regulators of gene expression in the post-transcription level and/or in the translation level. Several studies have shown that the process of their maturation is rather crucial for the development of cardiovascular system thus their regulation (up-,down-) is implicated with many cardiac pathologies. This is evaluated through their circulating levels which are reliable, stable and the changes in their serum profiles are representative of tissue alterations serum levels. Furthermore, they have been shown to participate in cardiovascular disease pathogenesis including atherosclerosis, coronary artery disease, myocardial infarction, heart failure cardiac arrhythmias and aortic stenosis. In the present review, we will first describe i) the process of miRNAs’ maturation ii) their role in the cardiovascular development, iii) their role as biomarkers of cardiac diseases, iv) the cardiac myo-miR families and the v) their role in cardiac remodeling and the development of cardiac diseases. Second we will review the miRNA families that participate in aortic stenosis separated according to its main pathways (imflammation, fibrosis, calcification). Finally, we will describe the miRNAs that participate in the development of aortic aneurysm and aortic dissection according to their serum levels.
Export Options
About this article
Cite this article as:
Vavuranakis Manolis, Kariori Maria, Vrachatis Dimitrios, Aznaouridis Konstantinos, Siasos Gerasimos, Kokkou Eleni, Mazaris Savvas, Moldovan Carmen, Kalogeras Konstantinos, Tousoulis Dimitris and Stefanadis Christodoulos, MicroRNAs in Aortic Disease, Current Topics in Medicinal Chemistry 2013; 13 (13) . https://dx.doi.org/10.2174/15680266113139990105
DOI https://dx.doi.org/10.2174/15680266113139990105 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Dendrimers as an Effective Nanocarrier in Cardiovascular Disease
Current Pharmaceutical Design Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Robotic Assisted Surgery in Gynecology: Current Insights and Future Perspectives
Recent Patents on Biotechnology Xenogeneic Decellularized Extracellular Matrix-based Biomaterials For Peripheral Nerve Repair and Regeneration
Current Neuropharmacology Synthesis of a Novel Series of 8-HETE Analogs and their Biological Evaluation Towards the PPAR Nuclear Receptors
Letters in Drug Design & Discovery Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets
Current Pharmaceutical Design Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued) Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy